All In Biotech

Drug Trial Radar · NCT06964087

Pharmacokinetic and Early Efficacy of OPT101 in Patients With Type 1 Diabetes Mellitus

A 48-week Phase 2 Multicenter Controlled Pharmacokinetic and Pilot Efficacy Trial of Subcutaneous OPT101 in Patients With Recent Onset Type 1 Diabetes Mellitus

Last checked: Nov 19, 2026Latest source record: Nov 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

72

Planned (sponsor's estimate)

Start

Apr 23, 2026

Primary completion

May 31, 2027

Study completion Aug 19, 2028

Sponsor

Lead sponsor
Op-T LLCIndustry
Sponsor type
Industry
First posted
May 9, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Sequential
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 50 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will examine the safety of three times weekly SC injections of OPT101 at each of three dose levels over two weeks as well as one year of treatment with SC OPT101 or placebo to match at a single dose level.

Conditions

  • Type I Diabetes

Interventions

  • OPT101Drug

    Subcutaneous injection.

  • OPT101 Placebo to Match (PTM)Other

    5% Dextrose (w/v)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in C-peptide (ng/mL)Time frame: 48-week

Locations

5 sites in 1 country. Site status is shown where the registry gives one.

  • University of Alabama at Birmingham - Department of Medicina

    Birmingham, Alabama · Recruiting

  • Diablo Clinical Research Center

    Walnut Creek, California · Recruiting

  • Barbara Davis Center - University of Colorado Anschuttz Medical Campus

    Aurora, Colorado · Recruiting

  • University of Chicago Medical Center

    Chicago, Illinois · Recruiting

  • Rainier Clinical Research Center

    Renton, Washington · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.